Genenta Science (GNTA) News Today → Obama’s Forever Term [exposed] (From Porter & Company) (Ad) Free GNTA Stock Alerts $3.18 -0.02 (-0.63%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15 at 3:54 AM | americanbankingnews.comGenenta Science (NASDAQ:GNTA) Rating Reiterated by HC WainwrightMay 10, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Cingulate Inc (CING) and Genenta Science SpA Sponsored ADR (GNTA)May 9, 2024 | marketbeat.comTrading was temporarily halted for "GNTA" at 10:05 AM with a stated reason of "LULD pause."May 8, 2024 | americanbankingnews.comGenenta Science (NASDAQ:GNTA) Shares Down 2% May 6, 2024 | finance.yahoo.comGenenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd WiderMay 6, 2024 | globenewswire.comGenenta Welcomes New Directors John L. Cantello, Lauren H.April 24, 2024 | marketbeat.comTrading was temporarily halted for "GNTA" at 11:04 AM with a stated reason of "LULD pause."April 11, 2024 | cnn.comGenenta Science SpA Sponsored ADRMarch 4, 2024 | msn.comBioVie stock plunges 43% following public offering pricingFebruary 20, 2024 | marketbeat.comTrading was temporarily halted for "GNTA" at 09:02 AM with a stated reason of "LULD pause."February 10, 2024 | markets.businessinsider.comBuy Rating for Genenta Science SpA on Strong Clinical Prospects and Innovative Gene Therapy PlatformFebruary 8, 2024 | finance.yahoo.comGenenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid TumorsFebruary 3, 2024 | finance.yahoo.comIs Genenta Science (NASDAQ:GNTA) In A Good Position To Invest In Growth?February 3, 2024 | marketbeat.comGenenta Science (NASDAQ:GNTA) Stock Price Down 7.2%Genenta Science (NASDAQ:GNTA) Trading Down 7.2%November 22, 2023 | marketbeat.comTrading was temporarily halted for "GNTA" at 11:11 AM with a stated reason of "LULD pause."November 14, 2023 | finance.yahoo.comIndividual investors account for 54% of Genenta Science S.p.A.'s (NASDAQ:GNTA) ownership, while insiders account for 30%August 18, 2023 | au.finance.yahoo.comGenenta Science S.p.A. (GNTA)July 28, 2023 | finance.yahoo.comGenenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor TreatmentsJuly 13, 2023 | marketbeat.comTrading was temporarily halted for "GNTA" at 12:07 PM with a stated reason of "LULD pause."July 8, 2023 | finance.yahoo.comHere's Why We're Not Too Worried About Genenta Science's (NASDAQ:GNTA) Cash Burn SituationJune 29, 2023 | finanznachrichten.deGENENTA SCIENCE SPA: The European Commission Grants Orphan Drug Designation to Temferon for Treatment of GliomaJune 29, 2023 | finance.yahoo.comThe European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of GliomaMay 17, 2023 | finance.yahoo.comInsiders own 30% of Genenta Science S.p.A. (NASDAQ:GNTA) shares but individual investors control 59% of the companyMay 16, 2023 | finance.yahoo.comGenenta to Provide Update on Lead Product Temferon™May 1, 2023 | marketbeat.comFY2023 Earnings Estimate for Genenta Science S.p.A. Issued By HC Wainwright (NASDAQ:GNTA)Genenta Science S.p.A. (NASDAQ:GNTA - Get Rating) - Analysts at HC Wainwright lowered their FY2023 EPS estimates for shares of Genenta Science in a research note issued on Wednesday, April 26th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($0.56April 28, 2023 | marketbeat.comHC Wainwright Comments on Genenta Science S.p.A.'s FY2027 Earnings (NASDAQ:GNTA)Genenta Science S.p.A. (NASDAQ:GNTA - Get Rating) - Analysts at HC Wainwright issued their FY2027 earnings estimates for shares of Genenta Science in a research report issued to clients and investors on Wednesday, April 26th. HC Wainwright analyst J. Pantginis anticipates that the company will eaApril 26, 2023 | finanznachrichten.deGENENTA SCIENCE SPA: Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F FilingApril 26, 2023 | finance.yahoo.comGenenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F FilingApril 3, 2023 | finance.yahoo.comGenenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor IndicationsMarch 2, 2023 | marketwatch.comGenenta Gets FDA Orphan-Drug Designation for Temferon in Glioblastoma Multiforme >GNTAMarch 2, 2023 | finance.yahoo.comFDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma MultiformeFebruary 24, 2023 | wsj.comGenenta Science S.p.A. ADRFebruary 8, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Genenta Science SpA Sponsored ADR (GNTA)February 7, 2023 | finance.yahoo.comGenenta Science and AGC Biologics Enter Development and Manufacturing Service AgreementJanuary 29, 2023 | finance.yahoo.comWe Think Genenta Science (NASDAQ:GNTA) Can Easily Afford To Drive Business GrowthDecember 8, 2022 | finance.yahoo.comGenenta Science S.p.A. (NASDAQ:GNTA) most popular amongst individual investors who own 60%, insiders hold 29%November 7, 2022 | finance.yahoo.comGenenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma PatientsOctober 24, 2022 | finance.yahoo.comGenenta Provides First Half 2022 Business Update and Financial ResultsOctober 5, 2022 | finance.yahoo.comGenenta to Present at Upcoming Scientific and Investor ConferencesSeptember 7, 2022 | finance.yahoo.comGenenta to Present at Upcoming Investor ConferencesAugust 22, 2022 | finance.yahoo.comWe're Not Very Worried About Genenta Science's (NASDAQ:GNTA) Cash Burn RateJuly 29, 2022 | marketbeat.comTrading was temporarily halted for "GNTA" at 09:07 AM with a stated reason of "LULD pause."July 27, 2022 | uk.investing.comThis Small Cap Cancer Company 'Hijacks Tumors From Within," HC Wainwright SaysJuly 27, 2022 | seekingalpha.comGene therapy developer Genenta Science named a buy at Wainwright on tumor approachJuly 25, 2022 | finance.yahoo.comAmCham Italy and Genenta Science Announce the Bowling Green Bull InitiativeJuly 25, 2022 | finance.yahoo.comAmCham Italy and Genenta Science Announce the Bowling Green Bull InitiativeJuly 14, 2022 | proactiveinvestors.com.auGenenta Science on track and well financed to begin phase II trial in 2023June 28, 2022 | marketbeat.comTrading was temporarily halted for "GNTA" at 10:06 AM with a stated reason of "LULD pause."June 28, 2022 | marketbeat.comTrading was temporarily halted for "GNTA" at 09:06 AM with a stated reason of "LULD pause."June 23, 2022 | marketbeat.comTrading was temporarily halted for "GNTA" at 03:06 PM with a stated reason of "LULD pause." Get Genenta Science News Delivered to You Automatically Sign up to receive the latest news and ratings for GNTA and its competitors with MarketBeat's FREE daily newsletter. Email Address Dems have chosen Biden replacement? (Ad)On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election. See who it is HERE. GNTA Media Mentions By Week GNTA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GNTA News Sentiment▼0.140.55▲Average Medical News Sentiment GNTA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GNTA Articles This Week▼50▲GNTA Articles Average Week Get Genenta Science News Delivered to You Automatically Sign up to receive the latest news and ratings for GNTA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Entera Bio News Today Cidara Therapeutics News Today LENZ Therapeutics News Today Aligos Therapeutics News Today Ikena Oncology News Today AVROBIO News Today Turnstone Biologics News Today Elutia News Today Atara Biotherapeutics News Today Instil Bio News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GNTA) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersInvest in the "Trojan Horse" of Alzheimer's TreatmentBehind the MarketsObama’s Forever Term [exposed]Porter & CompanyGold Set to EXPLODE!Gold Safe ExchangeThe 1,000X Crypto PlaybookTrue Market InsidersCharles Payne Demystifies OptionsUnstoppable ProsperityBiden FINISHED On June 13th?Paradigm PressWhy Is Gold On a MASSIVE rally? Huge AlertsShocking $16T Elon Musk Crypto LeakCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genenta Science S.p.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
